Novo Nordisk’s stock slumps after failed trial — adding to the company’s woes

The Danish healthcare company’s stock slumped on Friday after it announced the Phase 3 trial failure.

The experimental anti-inflammatory drug ziltivekimab did not reduce major adverse cardiovascular events compared with a placebo in a study of more than 6,300 patients

Novo Nordisk Shares Drop After Drug Candidate Fails in Cardiovascular Trial  WSJ

Shares of Novo Nordisk nosedived as much as 10% after the drugmaker said a late-stage heart drug trial failed to reduce major cardiovascular events compared to placebo.This is breaking news. Please refresh for updates.

New GSK CEO Luke Miels outlined his strategy to help the company navigate a patent cliff and get on a path toward long-term growth.

They're often cheaper and easier to get than Ozempic, but doctors say compounded GLP-1 drugs come with serious risks.

A new consensus by leading Indian endocrinologists recommends structured nutritional counselling for every patient taking GLP-1 weight loss drugs such as semaglutide and tirzepatide to preserve muscle and sustain weight loss. (Representative image)Weight loss drugs like semaglutide and tirzepatide have transformed the

Africa · Southern Key Facts —The recall. SAHPRA ordered a Class I, Type A recall of compounded semaglutide and tirzepatide products made by iDexis/Sentra Pharmacy. —The warning. Prescribers and pharmacists face fines from R25,000 to R75,000 (about US$1,500–US$4,600) and potential loss of licence. —The court case. Novo